Cantargia Ab · OMXSTO:CANTA
Cantargia Ab — Investor Presentation (September 2023)
20 slides from Cantargia Ab's investor presentation, Sep 14, 2023
Slide 1: Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases
Targeting IL1RAP to address unmet needs in severe cancer and autoimmune diseases Corporate Presentation Sep 2023 NASDAQ STOCKHOLM MAIN LIST (CANTA.ST)
Slide 2: Safe Harbor Statement
Safe Harbor Statement Statements in the Investor Presentation, including those regarding the possible or assumed future or other performance of the Company or its industry or other trend projections, constitute forward-looking statements. By their nature, forward-looking statements involve known and
Slide 3: Cantargia – Investment highlights
Cantargia – Investment highlights NOVEL IL1RAP ANTIBODIES, POTENTIAL TO TREAT CANCER & INFLAMMATORY DISEASE • IL1RAP elevated in most solid and liquid tumors • IL1RAP signalling drives several autoimmune and inflammatory diseases NADUNOLIMAB: CLEAR ACTIVITY SIGNALS IN CANCER THERAPY WITH UPCOMING CA
Slide 4: Current pipeline
Current pipeline Project Disease Type of Discovery Preclinical Clinical Clinical Clinical ' treatment — phase phase phase | phase Il phase III PDAC 1st line Gemcitabine/nab-paclitaxel Nadunolimab TNBC 49/2" line Carboplatin/gemcitabine or sa non-squamous NSCLC 154/26 line Platinum doublets Spent -_—
Slide 5: NADUNOLIMAB (CAN04)
NADUNOLIMAB (CAN04)
Slide 6: IL1RAP overexpressed in most solid tumors
IL1RAP overexpressed in most solid tumors IL1RAP EXPRESSION IN SOLID TUMOR TYPES SEVERAL TUMOR-PROMOTING CELLS EXPRESSING IL1RAP IN THE TUMOR MICROENVIRONMENT 100% IL1RAP-expressing tumors 75% 50% 25% 0% l C C st al ic er er ta SC CL at ge ea Liv d ec ad re NS HN ha Br r nc lo Bl op Co Pa Es Cancer
Slide 7: Pancreatic cancer – Positive interim data in 1st line patients
Pancreatic cancer – Positive interim data in 1st line patients Best responses according to iRECIST OS and iPFS for mITT patients Nadunolimab combination 50% Best change in tumor size with Gem/Abraxane in 1st line PDAC (n=73): 0% → 33% response rate with long PFS and OS -50% → Additional 5 (7%) patie
Slide 8: PDAC – Strong efficacy in patients with high tumor IL1RAP level
PDAC – Strong efficacy in patients with high tumor IL1RAP level IL1RAP High IL1RAP Low 50% Best change in tumor size iCPD 0% iUPD iSD iPR -50% -100% Efficacy analysis for IL1RAP High (n=27) vs IL1RAP Low (n=19) PDAC patients: → Significantly prolonged OS in ILRAP High vs IL1RAP Low patients (14.2 vs
Slide 9: PDAC – market opportunity
PDAC – market opportunity Expected number of cases US 2023: 64,000 Stage I - local: 3,200 Stage II - regional LN; 3,200 Stage IV - Stage III - metastatic: locally adv: 32,000 25,600 Stage I Stage II Stage III Stage IV RESECTABLE OR BORDERLINE RESECTABLE DISEASE LOCALLY ADVANCED OR METASTATIC DISEASE
Slide 10: NSCLC – Promising efficacy of nadunolimab combination therapy
NSCLC – Promising efficacy of nadunolimab combination therapy Best responses according to RECIST 50% Best change in tumor size 0% High ORR to nadunolimab and platinum 1L/2L NCG doublets in different lines of therapy: 1L/2L NCP → Gem/Cis 1st/2nd line: ORR 53% (n=30) ≥3L NCG -50% → Carbo/Pemtrex 1st/2
Slide 11: NSCLC – Long-term benefit with strong signal in non-squamous subtype
NSCLC – Long-term benefit with strong signal in non- squamous subtype Non- Treatment course for each individual patient All Historical Non-squamous squamous, (n=30) data1,2 (n=16) CR1 historical data3 Median OS 13.7 mo 10.3 mo 15.9 mo 11.3 mo CR2 Median PFS 7.0 mo 5.1 mo 7.3 mo 4.9 mo OS ORR 5
Slide 12: TNBC – Promising early safety and efficacy
TNBC – Promising early safety and efficacy Best responses according to RECIST Nadunolimab combination with Gem/Carbo in 100 % 1st/2nd line metastatic TNBC: Best change in tumor size 15 patients enrolled in the dose-escalation phase 50 % PD → Acceptable safety profile (G-CSF given prophylactically to
Slide 13: Key messages
Key messages Resistant → Most chemotherapies induce chemoresistance already after tumor Chemo- a few months of therapy. Chemotherapy can upregulate therapy both IL-1α and IL-1β, signaling through IL1RAP. → Clinical results strongly support potential unique first-in- class opportunities in PDAC, NSCL
Slide 14: CAN10 – Opportunity in autoimmune/inflammatory disease
CAN10 – OPPORTUNITY IN AUTOIMMUNE/INFLAMMATORY DISEASE
Slide 15: CAN10 – New clinical asset in autoimmunity/inflammation
CAN10 – New clinical asset in autoimmunity/inflammation → IL1RAP-binding antibody potently blocking IL-1, IL-33 and IL-36, without ADCC → Unique anti-inflammatory activity observed in different mouse models (myocarditis, systemic sclerosis, psoriasis, inflammation) → Development focusing on systemic
Slide 16: CAN10 – Promising effects in several preclinical disease models
CAN10 – Promising effects in several preclinical disease models Viral myocarditis Disease severity Autoimmune myocarditis Cardiac function 4 *** 1.1 Ratio to baseline * ** 3 1.0 * mCAN10 Ctrl mCAN10 Score 2 0.9 Anti-IL-1β Ctrl Anti-IL-1β Vehicle 1 0.8 0 0.7 0 10 20 30 40 cle A l 0 ro 1R N1 Day nt hi
Slide 17: CAN10 – Project status
CAN10 – Project status Status → CAN10 safe in GLP tox study → Strong results in preclinical models of several diseases including lead indications myocarditis and systemic sclerosis → Phase I ongoing, early planning of patient studies (phase IIa) Clinical phase I study – First data set during 2024 →
Slide 18: Milestones & Investment Highlights
MILESTONES & INVESTMENT HIGHLIGHTS
Slide 19: Upcoming milestones
Upcoming milestones Nadunolimab Additional PDAC NSCLC TNBC CAN10 milestones • New translational • Efficacy/biomarker • Randomized Phase II • Phase I recruitment • New clinical data data Q3 2023 data from CANFOUR (TRIFOUR) – interim and treatment presented from 2023 and 2024 futility analysis in Q4 o
Slide 20: Cantargia – Investment highlights
Cantargia – Investment highlights NOVEL IL1RAP ANTIBODIES, POTENTIAL TO TREAT CANCER & INFLAMMATORY DISEASE • IL1RAP elevated in most solid and liquid tumors • IL1RAP signalling drives several autoimmune and inflammatory diseases CLEAR ACTIVITY SIGNALS IN CANCER THERAPY; WITH UPCOMING CATALYSTS • St